LifeCore Biomedical Files 8-K on Shareholder Votes

TL;DR

LIFECORE BIOMEDICAL (LNDC) filed an 8-K on Nov 7th regarding shareholder votes. Nothing else significant.

AI Summary

LifeCore Biomedical, Inc. filed an 8-K on November 8, 2024, reporting on matters submitted to a vote of security holders as of November 7, 2024. The filing indicates the company is incorporated in Delaware and its principal executive offices are located in Chaska, Minnesota.

Why It Matters

This filing informs investors about significant corporate actions or decisions that have been put to a vote by the company's shareholders.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of a shareholder vote and does not appear to contain any new material financial or operational information.

Key Players & Entities

• LIFECORE BIOMEDICAL, INC. (company) — Registrant
• Delaware (jurisdiction) — State of incorporation
• Chaska, Minnesota (location) — Principal executive offices
• November 7, 2024 (date) — Date of earliest event reported
• November 8, 2024 (date) — Date of report

FAQ

Key Financial Figures

• $0.001 — f the Company's common stock, par value $0.001 per share (the "Common Stock") outstand

Filing Documents

• lndc-20241107.htm (8-K) — 44KB
• 0001005286-24-000163.txt ( ) — 168KB
• lndc-20241107.xsd (EX-101.SCH) — 2KB
• lndc-20241107_lab.xml (EX-101.LAB) — 22KB
• lndc-20241107_pre.xml (EX-101.PRE) — 13KB
• lndc-20241107_htm.xml (XML) — 3KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. On November 7, 2024, Lifecore Biomedical. Inc. (the "Company") held its 2024 Annual Meeting of Stockholders (the "Annual Meeting"). As of the close of business on October 4, 2024, the record date for the Annual Meeting (the "Record Date"), there were (i) 36,855,072 shares of the Company's common stock, par value $0.001 per share (the "Common Stock") outstanding and entitled to vote at the Annual Meeting, (ii) 44,067 shares of the Company's Series A Convertible Preferred Stock, par value $0.001 per share (the "Series A Preferred Stock") outstanding, (iii) 44,067 shares of Series A Preferred Stock entitled to vote on the Series A Preferred Director (as defined below), and (iv) 44,067 shares of Series A Preferred Stock entitled to vote on an as-converted basis (voting together with the holders of shares of Common Stock as one class), subject to the applicable conversion limits, on the other applicable nominees and proposals (representing, on an as-converted basis, the equivalent of 5,889,404 shares of Common Stock). The three proposals presented to the stockholders of the Company at the Annual Meeting were: (1) To elect five director nominees to serve for a term expiring at the 2025 Annual Meeting and until their successors are duly elected and qualified, with four such nominees to be elected by holders of Common Stock and holders of the Series A Preferred Stock, voting together as a single class, and one nominee to be elected solely by holders of the Series A Preferred Stock (the latter, the "Series A Preferred Director"). (2) To ratify the appointment of BDO USA, P.C. as the Company's independent registered public accounting firm for the fiscal year ending May 25, 2025. (3) To approve a non-binding advisory proposal on the executive compensation of the Company's named executive officers. 1. Stockholders elected five director nominees and the voting results were as follows: Directors Elected by A

View Full Filing

View this 8-K filing on SEC EDGAR